Tendons are specialised collagenous tissues that transmit muscle force to bone with minimal elasticity—a design that makes them prone to partial tears and degeneration when overstressed.
Tendons are specialised collagenous tissues that transmit muscle force to bone with minimal elasticity—a design that makes them prone to partial tears and degeneration when overstressed. Unlike muscle, tendons have poor intrinsic healing capacity due to limited blood supply and sparse resident cell populations. Recovery from tendon injury often stalls at a fibrotic scar that is weaker and less organised than native tissue. Cell therapy approaches employ placental MSCs, exosomes (acellular vesicles carrying molecular signals), and sometimes engineered chondrocytes to promote tissue remodelling and fibril alignment. The proposed mechanism involves delivering cells or their secreted factors directly to the injury site, where they are thought to reduce inflammation, promote angiogenesis (new blood vessel formation), and guide collagen deposition along physiologically correct orientations.
| Indicative cost · Bulgaria (EU) | €3,000–€8,000 |
|---|---|
| Global market cost range | €3,680–€9,200 (dvcstem.com) |
| Main cell types studied | MSCs from Amniotic Membrane, Exosomes, Chondrocytes |
| Approval status | Investigational |
| Registered trials (ClinicalTrials.gov) | 22 · 1 recruiting now |
For the clinic's own description, see our partner clinic Stem Plus.
The tendon-injury cell-therapy landscape encompasses 22 completed trials and 1 actively recruiting study. Most involve placental MSC injections or exosome preparations administered directly into the tendon lesion under ultrasound guidance. Trial cohorts typically include both acute partial tears and chronic degenerative tendinopathy. Imaging outcomes (ultrasound, MRI) in small studies show improved fibre continuity and reduced fluid signal in approximately 50–70% of treated tendons. Functional metrics (strength, pain reduction, return-to-activity) vary by trial; some report 60–80% of athletes returning to sport within 6–12 months, though untreated controls are rarely present for comparison.
Depending on assessment, a Tendon & Sports Injuries protocol may draw on:
Tendon-directed cell therapy costs €3,500–6,500 per session, reflecting the technical demand of ultrasound-guided injection, cell preparation, and quality assurance. Imaging—baseline and follow-up ultrasound or MRI—adds €600–1,500. Participants intending to return to elite sport often pursue two or three injections spaced 6–8 weeks apart, bringing total cost to €10,000–18,000; many centres recommend 6- and 12-month follow-up imaging.
Indicative EU treatment cost is €3,000–€8,000 versus roughly €15,000–35,000 in the US or Germany. Build your real all-in total with the cost calculator, or see the Tendon & Sports Injuries cost-by-country breakdown.
Before booking, check safety & regulation, the recovery climate, whether you may be a candidate, and which cell type fits Tendon & Sports Injuries.
Full Tendon & Sports Injuries FAQ → · Tendon & Sports Injuries cost breakdown →
We link primary regulators, registries and peer-reviewed research so you can verify everything yourself — plus the treating clinic's own materials.
Useful tools & guides: Am I a candidate? · Which cell type? · Types of clinics & best countries · Cost calculator
Medically reviewed by StemCellAtlas’s editorial team with Dr Tymur Lukyanenko (Orthopaedic Traumatologist · 20+ yrs clinical, 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
Médecine régénérative certifiée GMP au cœur de l'UE — à partir de 3 000–8 000 €, une fraction des prix américains ou allemands. Protocoles personnalisés pour patients de plus de 50 pays.
Évaluation médicale gratuite